Abstract
Pancreatic cancer is a highly aggressive tumor. Due to the lack of characteristic symptoms, it is usually detected in the advanced stage. Resection of the tumor is possible only in 10-20% of all patients, which significantly extends and improves the quality of their life. Therefore, new diagnostic methods are sought to detect PCDA at an early stage. Biomarkers are also increasingly being used in the diagnosis of pancreatic cancer, as well as genetic testing to better identify those at risk and use screening among them. Despite the development of treatments for pancreatic cancer, it still has a low 5-year survival rate, so there is a constant need for research into more effective therapeutic modalities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
